Acer Medical (6857) H2 2025 earnings summary

Executive summary

• Auditor issued an unqualified opinion for the years ended December 31, 2024 and 2023, confirming financial statements are fairly presented in all material respects according to regulatory standards.

• Key audit matter identified: revenue recognition for consignment sales from an equity-method subsidiary, with manual verification of shipments and receipts.

Financial highlights

• Revenue for 2024 was NT$43,216K, up 18% year-over-year from NT$36,612K.

• Net loss for 2024 was NT$29,686K, compared to NT$27,364K in 2023.

• Gross margin improved to 64% in 2024 from 50% in 2023.

• Operating expenses increased to NT$58,737K (136% of revenue) from NT$51,091K (140% of revenue) year-over-year.

• Basic and diluted loss per share were NT$1.95 in 2024, compared to NT$1.80 in 2023.

Outlook and guidance

• No dividends or profit distribution due to accumulated losses; capital management focused on maintaining sufficient resources for future operations.